Edgewood Oncology Announces New Efficacy Data From Investigator-Sponsored Study of BTX-A51 in Preclinical Models of Liposarcoma
BROOKLINE, Mass.--(BUSINESS WIRE)--Edgewood Oncology, a clinical-stage biotechnology company focused on delivering BTX-A51 to patients with hematologic malignancies and genetically-defined solid tumors, today announced the presentation of new preclinical data presented by Dana-Farber Cancer Institute and Hebrew University-Hadassah Medical School in support of an ongoing investigator-sponsored Phase 1 study of BTX-A51 in liposarcoma (LPS) at the American Association of Cancer Research (AACR) Annual Meeting taking place April 25-30, 2025, in Chicago.
BTX-A51 is a first-in-class, small molecule kinase inhibitor that co-targets casein kinase 1 alpha (CK1α and cyclin-dependent kinases 7 and 9 (CDK7 and CDK9), three master regulators of cancer cell survival and transcriptional control.
The presentation, ' Therapeutic potential of combined targeting of casein kinase 1 alpha (CK1α) and CDK7/9 with the inhibitor BTX-A51 in human liposarcomas,' highlights new mechanistic and efficacy data in patient-derived cell lines and xenograft models. One of the most significant findings from the presentation is that CK1α is an essential gene for the growth of liposarcomas based on genome-scale RNAi perturbation analysis. The study also used RNAi knockdown and targeted small molecules to confirm that inhibition of CK1α, CDK7, and CDK9 has synergistic impacts on LPS cell survival. As a single agent, BTX-A51 blocked MDM2 and induced P53 expression, stimulating potent apoptosis in LPS models while significantly inhibiting tumor growth in patient-derived xenografts at well tolerated dose levels.
'Well-differentiated and dedifferentiated liposarcomas (WD/DDLPS) remain among the most challenging soft tissue sarcomas to treat,' said Geoffrey I. Shapiro, M.D., Ph.D., Professor of Medicine, Harvard Medical School, and director of the Early Drug Development Center at Dana-Farber Cancer Institute. 'This study identifies novel, targetable vulnerabilities in LPS and offers a compelling justification for the clinical evaluation of BTX-A51 in this patient population.'
BTX-A51 is currently being evaluated in an open-label, investigator-sponsored Phase 1 pilot study at Dana-Farber Cancer Institute in patients with metastatic and/or recurrent liposarcomas characterized by Murine Double Minute Clone 2 (MDM2) amplifications. Additional details about the study can be found at clinicaltrials.gov under the identifier NCT06414434.
'These findings strengthen the rationale for BTX-A51's mechanism of action and support its potential across a spectrum of genetically defined cancers,' said David N. Cook, Ph.D., Chief Executive Officer of Edgewood Oncology. 'We're encouraged by the strength of these preclinical findings, which further support the ongoing clinical advancement of BTX-A51.'
Additional Details about the Study
Through computational and experimental methods, including DepMap screening, siRNA silencing, and small-molecule inhibitor profiling, the study confirmed that CK1α, CDK7, and CDK9 are essential for LPS survival. CK1α knockdown by itself was shown to be toxic to LPS cell lines and CDK9 inhibition alone suppressed LPS cell growth and induced apoptosis by downregulating MDM2 and activating p53. When CK1α depletion and CDK9 inhibition were combined, the potency of the individual approaches was amplified. In addition, combining CDK7 and CDK9 inhibitors synergistically inhibited LPS cell lines. These observations led to the evaluation of BTX-A51, which inhibits all three kinases with nanomolar potency. BTX-A51 robustly reduced MDM2 expression and induced expression of p53 and PUMA. The compound also lowered MCL1 expression and sensitized cells to apoptotic signaling through BIM and PUMA, as confirmed by BH3 profiling. In vivo studies in two LPS PDX models demonstrated that BTX-A51 is well tolerated and inhibits tumor growth under clinically relevant dosing conditions.
Citation:
Liu, R., Solimini, N. L., McSweeney, C., Bhola, P., Griffin, D., Branigan, T. B., Wagner, M. J., Turchick, A., de Matos Simoes, R., Dempster, J. M., Hao, J., Wang, X., Alharthi, R., Yorsz, M., Soni, S., Hu, C., Snir-Alkalay, I., Vazquez, F., Gokhale, P. C., Mitsiades, C., Letai, A., Ben-Neriah, Y., Demetri, G. D., & Shapiro, G. I. (2025). Therapeutic potential of combined targeting of casein kinase 1 alpha (CK1α) and CDK7/9 with the inhibitor BTX-A51 in human liposarcomas [Poster presentation]. American Association for Cancer Research (AACR) Annual Meeting 2025, Chicago, IL, United States.
About Edgewood Oncology
Edgewood Oncology is a clinical-stage biotechnology company that was founded to deliver on the promise of BTX-A51 for patients with hematologic malignancies and genetically-defined solid tumors. BTX-A51 is a novel small molecule, multi-kinase inhibitor that synergistically co-targets master regulators of cancer to activate programmed cell death, or apoptosis. BTX-A51 holds promise in acute myeloid leukemia and genetically-defined solid tumors, which are the focus of ongoing clinical programs. For more information, please visit www.edgewoodoncology.com, and follow us on LinkedIn.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
38 minutes ago
- Yahoo
AIG Announces Reference Yields and Total Consideration for its Tender Offers for Certain Outstanding Notes
NEW YORK, June 06, 2025--(BUSINESS WIRE)--American International Group, Inc. (NYSE: AIG) today announced the pricing terms for each series of the Notes included in its previously announced tender offers (the "Offers") to purchase outstanding notes of the series listed in the table below (collectively, the "Notes") for cash up to a maximum $300 million aggregate amount of Total Consideration (as defined below), excluding the Accrued Coupon Payment (as defined below). The Offers are being made pursuant to AIG's Offer to Purchase, dated June 2, 2025 (the "Offer to Purchase"), which sets forth a more comprehensive description of the terms and conditions of each Offer, and the accompanying notice of guaranteed delivery (the "Notice of Guaranteed Delivery" and, together with the Offer to Purchase, the "Tender Offer Documents"). Capitalized terms used but not defined in this announcement have the meanings given to them in the Offer to Purchase. Set forth below are the applicable Reference Yields and Total Consideration for each series of Notes, as calculated at 10:00 a.m. today, June 6, 2025, in accordance with the Offer to Purchase. AcceptancePriorityLevel(1) Title of Security CUSIP/ISIN First Par CallDate(2) Maturity Date Principal AmountOutstanding(millions) ReferenceSecurity(3) ReferenceSecurityYield FixedSpread(basispoints)(3) BloombergReferencePage TotalConsideration(2)(3) 1 5.750% Series A-9 Junior Subordinated Debentures Due 2048(4) 026874DM6 /US026874DM66 April 1, 2028 April 1, 2048 $439.0 3.750% UST due 05/15/2028 4.003% 140 bps FIT1 $1,008.84 2 8.175% Series A-6 Junior Subordinated Debentures Due 2058(4) 026874BS5 /US026874BS54 May 15, 2038 May 15, 2058 $146.9 4.250% UST due 05/15/2035 4.474% 210 bps FIT1 $1,137.94 3 6.820% Notes Due 2037 026874CW5 /US026874CW57 N/A November 15, 2037 $78.4 4.250% UST due 05/15/2035 4.474% 90 bps FIT1 $1,129.84 4 6.250% Notes Due 2036 026874AZ0 /US026874AZ07 N/A May 1, 2036 $285.2 4.250% UST due 05/15/2035 4.474% 85 bps FIT1 $1,075.72 5 6.250% Series A-1 Junior Subordinated Debentures Due 2037 026874BE6 /US026874BE68 N/A March 15, 2037 $20.9 4.250% UST due 05/15/2035 4.474% 200 bps FIT1 $981.63 6 4.800% Notes Due 2045 026874DF1 /US026874DF16 January 10, 2045 July 10, 2045 $436.8 5.000% UST due 05/15/2045 4.962% 70 bps FIT1 $897.32 7 4.250% Notes Due 2029 026874DN4 /US026874DN40 December 15, 2028 March 15, 2029 $191.8 4.000% UST due 05/31/2030 4.093% 60 bps FIT1 $984.82 8 4.200% Notes Due 2028 026874DK0 /US026874DK01 January 1, 2028 April 1, 2028 $341.0 3.750% UST due 05/15/2028 4.003% 40 bps FIT1 $994.64 9 4.700% Notes Due 2035 026874DE4 /US026874DE41 January 10, 2035 July 10, 2035 $164.0 4.250% UST due 05/15/2035 4.474% 80 bps FIT1 $955.51 10 4.375% Notes Due 2055 026874DB0 /US026874DB02 July 15, 2054 January 15, 2055 $188.7 4.625% UST due 02/15/2055 4.945% 135 bps FIT1 $743.65 (1) Subject to the satisfaction or waiver of the conditions of the Offers described in the Offer to Purchase, if the Maximum Purchase Condition is not satisfied with respect to every series of Notes, AIG will accept Notes for purchase in the order of their respective Acceptance Priority Level specified in the table above (with 1 being the highest Acceptance Priority Level and 10 being the lowest Acceptance Priority Level). It is possible that a series of Notes with a particular Acceptance Priority Level will not be accepted for purchase even if one or more series with a higher or lower Acceptance Priority Level are accepted for purchase. (2) For each series of Notes in respect of which a par call date is indicated, the calculation of the applicable Total Consideration was performed to either the maturity date or such par call date, in accordance with standard market convention. See Annex A to the Offer to Purchase for an overview of the calculation of the Total Consideration (including the par call detail) with respect to the Notes. (3) The Total Consideration for each series of Notes (such consideration, the "Total Consideration") payable per each $1,000 principal amount of such series of Notes validly tendered for purchase, has been calculated based on the fixed spread specified in the table above for such series of Notes, plus the yield of the specified Reference Security for that series as quoted on the Bloomberg reference page specified in the table above as of 10:00 a.m. (Eastern time). The Total Consideration does not include the applicable Accrued Coupon Payment, which will be payable in cash in addition to the applicable Total Consideration. (4) For the avoidance of doubt, for purposes of calculating the applicable Total Consideration, it has been assumed that payments on the 5.750% Series A-9 Junior Subordinated Debentures Due 2048 and the 8.175% Series A-6 Junior Subordinated Debentures Due 2058 are made through the applicable par call date regardless of the Offer Yield, in accordance with standard market practice. Each Offer will expire at 5:00 p.m. (Eastern time) on June 6, 2025, unless extended or earlier terminated (such date and time with respect to an Offer, as the same may be extended with respect to such Offer, the "Expiration Date"). Notes may be validly withdrawn at any time at or prior to 5:00 p.m. (Eastern time) on the Expiration Date but not thereafter, unless extended by AIG. For Holders who deliver a Notice of Guaranteed Delivery and all other required documentation at or prior to the Expiration Date, upon the terms and subject to the conditions set forth in the Tender Offer Documents, the deadline to validly tender Notes using the Guaranteed Delivery Procedures will be the second business day after the Expiration Date and is expected to be 5:00 p.m. (Eastern time) on June 10, 2025 (the "Guaranteed Delivery Date"). The "Initial Settlement Date" will be the second business day after the Expiration Date and is expected to be June 10, 2025. The "Guaranteed Delivery Settlement Date" will be the second business day after the Guaranteed Delivery Date and is expected to be June 12, 2025. Upon the terms and subject to the conditions set forth in the Offer to Purchase, Holders whose Notes are accepted for purchase in the Offers will receive the applicable Total Consideration for each $1,000 principal amount of such Notes in cash on the Initial Settlement Date or Guaranteed Delivery Settlement Date, as applicable. In addition to the applicable Total Consideration, Holders whose Notes are accepted for purchase will receive a cash payment equal to the accrued and unpaid interest on such Notes from and including the immediately preceding interest payment date for such Notes to, but excluding, the Initial Settlement Date (the "Accrued Coupon Payment"). Interest will cease to accrue on the Initial Settlement Date for all Notes accepted in the Offers and Holders whose Notes are tendered pursuant to the Guaranteed Delivery Procedures and are accepted for purchase will not receive payment in respect of any interest for the period from and including the Initial Settlement Date. AIG has retained BNP Paribas Securities Corp., BofA Securities, Inc. and U.S. Bancorp Investments, Inc. as the Lead Dealer Managers. Global Bondholder Services Corporation is the Information Agent and Tender Agent. For additional information regarding the terms of the tender offer, please contact: BNP Paribas Securities Corp. at (888) 210-4358 (toll-free) or (212) 841-3059 (collect); BofA Securities, Inc. at (888) 292-0070 (toll-free) or (980) 387-3907 or U.S. Bancorp Investments, Inc. at (800) 479-3441 (toll-free) or (917) 558-2756 (collect). Requests for documents and questions regarding the tendering of Notes may be directed to Global Bondholder Services Corporation by telephone at (212) 430-3774 (for banks and brokers only) and (855) 654-2014 (for all others toll-free), by email at contact@ or to the Lead Dealer Managers at their respective telephone numbers. Copies of the Offer to Purchase and the Notice of Guaranteed Delivery are available at The Offers are subject to the satisfaction of certain conditions. AIG may terminate or alter any or all of the Offers and is not obligated to accept for payment, purchase or pay for, and may delay the acceptance for payment of, any tendered Notes, in each event subject to applicable laws. The Offers are not conditioned on the tender of a minimum principal amount of Notes. Beneficial owners of Notes are advised to check with any bank, securities broker or other intermediary through which they hold Notes as to when such intermediary would need to receive instructions from a beneficial owner in order for that beneficial owner to be able to participate in, or withdraw their instruction to participate in, an Offer before the deadlines specified in this press release. The deadlines set by any such intermediary and the Depository Trust Company for the submission and withdrawal of tender instructions may be earlier than the relevant deadlines specified in this press release. This press release is neither an offer to purchase nor a solicitation of an offer to sell the Notes or any other securities. The Offers are made only by and pursuant to the terms of the Offer to Purchase and only to such persons and in such jurisdictions as is permitted under applicable law. The information in this press release is qualified by reference to the Offer to Purchase. None of AIG, the dealer managers or the tender and information agent makes any recommendations as to whether Holders should tender their Notes pursuant to the Offers. Holders must make their own decisions as to whether to tender Notes, and, if so, the principal amount of Notes to tender. # # # Certain statements in this press release, including those describing the completion of the Offers, constitute forward-looking statements. These statements are not historical facts but instead represent only AIG's belief regarding future events, many of which, by their nature, are inherently uncertain and outside AIG's control. It is possible that actual results will differ, possibly materially, from the anticipated results indicated in these statements. Factors that could cause actual results to differ, possibly materially, from those in the forward-looking statements are discussed throughout AIG's periodic filings with the SEC pursuant to the Securities Exchange Act of 1934. # # # About AIG American International Group, Inc. (NYSE: AIG) is a leading global insurance organization. AIG provides insurance solutions that help businesses and individuals in more than 200 countries and jurisdictions protect their assets and manage risks through AIG operations, licenses and authorizations as well as network partners. For additional information, visit This website with additional information about AIG has been provided as a convenience, and the information contained on such website is not incorporated by reference into this press release. AIG is the marketing name for the worldwide operations of American International Group, Inc. All products and services are written or provided by subsidiaries or affiliates of American International Group, Inc. Products or services may not be available in all countries and jurisdictions, and coverage is subject to underwriting requirements and actual policy language. Non-insurance products and services may be provided by independent third parties. Certain property casualty coverages may be provided by a surplus lines insurer. Surplus lines insurers do not generally participate in state guaranty funds, and insureds are therefore not protected by such funds. View source version on Contacts Quentin McMillan (Investors): Claire Talcott (Media): Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
42 minutes ago
- Business Wire
Leading Proxy Advisory Firm ISS Recommends PENN Entertainment Shareholders Vote 'FOR' All Three Director Candidates Nominated by HG Vora
NEW YORK--(BUSINESS WIRE)--HG Vora Capital Management, LLC (together with its affiliates, 'HG Vora') today announced that Institutional Shareholder Services Inc. ('ISS'), a leading independent proxy advisory firm, has recommended that shareholders of PENN Entertainment, Inc. (NASDAQ: PENN) ('PENN' or the 'Company') cast their votes 'FOR' the election of all three independent director candidates nominated by HG Vora – William Clifford, Johnny Hartnett, and Carlos Ruisanchez – to the Company's Board of Directors (the 'Board') on the GOLD proxy card at PENN's 2025 Annual Meeting of Shareholders (the 'Annual Meeting'), scheduled for June 17, 2025. In its report,* ISS concluded that PENN's performance under current leadership has 'been disappointing over all measurement periods', that the Board's misguided interactive strategy has 'failed to drive the returns expected by shareholders', and that there is 'clearly a case for board change' given there is 'little evidence that the board has been able to hold management accountable.' With respect to PENN's significant underperformance and strategic errors under the current Board, ISS said: 'The company's push into interactive has not been successful.' 'The overall story is one of M&A that has generally failed to drive the returns expected by shareholders.' 'It is particularly difficult to overlook the negative inflection that coincided with expansion into online sports betting, which is highlighted by the dissident.' 'Most worryingly, the company has pursued acquisitions and partnerships since early 2020 that have failed to meet the expectations of shareholders, and failed to meet the company's own stated goals.' 'The board appears not to have taken tangible lessons from its record in approving company acquisitions.' With respect to the Board's composition, poor corporate governance, and lack of management oversight, ISS said: 'The board lacks an adequate level of direct gaming industry experience. It appears that this deficiency has hampered the board's ability to effectively oversee management during the push into interactive, which has in turn translated into disappointing TSR and operational results.' '[T]here is little evidence that the board has been able to hold management accountable, as the company has continued to pursue a strategy that has failed to deliver on expectations.' With respect to the qualifications of the three independent director candidates, ISS said: 'Hartnett and Ruisanchez seem to have fortuitously presented the board with a ready-made solution to a problem it was otherwise unprepared to address.' 'The more important point is that the board requires additional direct gaming industry experience, which Clifford can impart. He also has experience at the company itself, as a member of senior management and recently as a consultant.' '[With respect to Clifford …], there is little evidence that the board has been able to hold management accountable, which suggests that a director who is not afraid to share a contrarian viewpoint may be a valuable addition.' 'There does not appear to be an outcome that would make support unwarranted for Clifford at this meeting.' In conclusion, ISS said, 'support for Clifford, as well as Hartnett and Ruisanchez, is warranted on the dissident card.' Previously, leading independent proxy advisory firm Egan-Jones Proxy Services also recommended that PENN shareholders cast their votes 'FOR' the election of all three independent director candidates nominated by HG Vora – William Clifford, Johnny Hartnett, and Carlos Ruisanchez – to the Board using the GOLD proxy card at PENN's 2025 Annual Meeting. To ensure the election of William Clifford, Johnny Hartnett, and Carlos Ruisanchez, it is essential that all PENN shareholders vote the GOLD proxy card 'FOR' HG Vora's highly qualified director nominees – William Clifford, Johnny Hartnett, and Carlos Ruisanchez. With PENN's Annual Meeting less than two weeks away, it is important that shareholders cast their votes today. Every vote is important, no matter how many shares you own. If you have any questions about how to vote your shares, please contact our proxy solicitor Okapi Partners by telephone at 877-629-6355 or email at info@ For more information, including voting instructions, visit our website *HG Vora has neither sought nor obtained consent from ISS to use previously published information in this press release Cautionary Statement Regarding Forward-Looking Statements The information herein contains 'forward-looking statements' that can be identified by the fact that they do not relate strictly to historical or current facts. Specific forward-looking statements can be identified by the fact that they do not relate strictly to historical or current facts and include, without limitation, words such as 'may,' 'will,' 'expects,' 'believes,' 'anticipates,' 'plans,' 'intends,' 'estimates,' 'projects,' 'potential,' 'targets,' 'forecasts,' 'seeks,' 'could,' 'should' or the negative of such terms or other variations on such terms or comparable terminology. Similarly, statements that describe our objectives, plans or goals are forward-looking. Forward-looking statements are subject to various risks and uncertainties and assumptions. There can be no assurance that any idea or assumption herein is, or will be proven, correct. If one or more of the risks or uncertainties materialize, or if HG Vora's underlying assumptions prove to be incorrect, the actual results may vary materially from outcomes indicated by these statements. Accordingly, forward-looking statements should not be regarded as a representation by HG Vora that the future plans, estimates or expectations contemplated will ever be achieved. The information herein does not constitute an offer to sell or solicitation of an offer to buy any of the securities described herein in any state to any person. Certain Information Concerning the Participants HG Vora and the other Participants (as defined below) filed a definitive proxy statement and accompanying gold universal proxy card with the SEC on May 12, 2025 to be used to solicit proxies for the election of its slate of director nominees at the 2025 annual meeting of shareholders (the '2025 Annual Meeting') of PENN Entertainment, Inc. ('PENN'). The participants in the proxy solicitation are currently anticipated to be HG Vora Capital Management, LLC (the 'Investment Manager'), HG Vora Special Opportunities Master Fund, Ltd. ('Master Fund'), Downriver Series LP – Segregated Portfolio C ('Downriver'), Parag Vora ('Mr. Vora' and, collectively with Investment Manager, Master Fund and Downriver, 'HG Vora'), Johnny Hartnett, Carlos Ruisanchez and William Clifford (collectively all of the foregoing, the 'Participants'). As of the date hereof, (i) Master Fund directly owns 3,825,000 shares of common stock, par value $0.001 per share (the 'Common Stock'), of PENN, including 100 shares of Common Stock as the record holder and (ii) Downriver directly owns 3,425,000 shares of Common Stock, including 100 shares of Common Stock as the record holder (collectively, the 7,250,000 shares of Common Stock owned by Master Fund and Downriver, the 'HG Vora Shares'). The HG Vora Shares collectively represent approximately 4.80% of the outstanding shares of Common Stock, based on the 150,852,769 shares of Common Stock outstanding as of April 24, 2025, as disclosed by PENN on its proxy statement for the Annual Meeting. The Investment Manager is the investment manager of Master Fund and Downriver, each of which have delegated all investment and voting decisions to the Investment Manager. Mr. Vora is the manager of the Investment Manager and has authority over day-to-day operations and investment and voting decisions, including with respect to the HG Vora Shares, of the Investment Manager. Each of the Investment Manager and Mr. Vora may be deemed to have the shared power to vote or direct the vote of (and the shared power to dispose or direct the disposition of) the HG Vora Shares and indirect ownership thereof. Mr. Ruisanchez directly owns 3,150 shares of Common Stock. Neither Mr. Clifford nor Mr. Hartnett beneficially own any shares of Common Stock. Certain of the Participants are also from time to time party to certain derivative instruments that provide economic exposure to PENN's Common Stock. All of the foregoing information is as of the date hereof unless otherwise disclosed. Important Information and Where to Find It HG VORA STRONGLY ADVISES ALL SHAREHOLDERS OF THE CORPORATION TO READ THE DEFINITIVE PROXY STATEMENT AND OTHER PROXY MATERIALS BECAUSE THEY CONTAIN IMPORTANT INFORMATION. SUCH PROXY MATERIALS ARE AVAILABLE AT NO CHARGE ON THE SEC'S WEBSITE AT THE DEFINITIVE PROXY AND ACCOMPANYING PROXY CARD WILL ALSO BE FURNISHED TO SOME OR ALL OF THE COMPANY'S SHAREHOLDERS. SHAREHOLDERS MAY DIRECT A REQUEST TO THE PARTICIPANTS' PROXY SOLICITOR, OKAPI PARTNERS LLC, 1212 AVENUE OF THE AMERICAS, 17TH FLOOR, NEW YORK, NEW YORK 10036 (SHAREHOLDERS CAN CALL TOLL-FREE: (877) 629-6355).
Business Wire
an hour ago
- Business Wire
BRE Celebrates U.S. Market Excellence at the 2025 BREEAM Awards
SAN FRANCISCO--(BUSINESS WIRE)--The Building Research Establishment (BRE) recognized significant achievements in the U.S. market at the 2025 BREEAM Awards, which honored the people and projects leading the industry in sustainable building design, development and management. Held in London on Thursday, June 5, the awards brought together leaders from across the global built environment to celebrate accomplishments across BREEAM's network, reinforcing the role of sustainability strategies in driving long-term value and resilience. While the following U.S. nominees did not receive the top award in their respective categories, being shortlisted reflects an immense achievement and underscores the caliber of their work in advancing sustainability within the built environment. The 2025 U.S. shortlisted nominees include: DWS US Portfolio, GRESB Portfolio Integration Award PGIM Real Estate, GRESB Portfolio Integration Award CBRE Inc, Best Assessor Company Cushman & Wakefield, Best Assessor Company GreenGen, Best Assessor Company Iron Mountain Data Centers, BREEAM NC Commercial Chris Pennington, BREEAM ESG Outstanding Achievement Award This year's U.S. nominees were recognized across several categories, reflecting the growing dominance of BREEAM as a science-driven framework for improving performance, operational excellence and value creation in U.S. real estate. 'In today's economic climate, real estate owners, investors and operators are under pressure to demonstrate the value and resilience of their assets,' said Breana Wheeler, U.S. Director of Operations at BRE. 'The projects and professionals recognized at this year's BREEAM Awards demonstrate what's possible when sustainability goals are treated as drivers of operational excellence, and we're proud to celebrate their achievements." The event also commemorated a major milestone for BREEAM and citizenM, with the hospitality brand's Menlo Park Hotel becoming the first hotel in the U.S. to achieve an Outstanding rating under BREEAM In-Use – the highest level of certification available. Chosen as the hotel partner for Meta's campus in Menlo Park, California, the Menlo Park property was designed to meet rigorous sustainability, well-being and efficiency goals. The project serves as a benchmark for sustainable hospitality in the U.S., demonstrating how early planning, data-driven decision making and stakeholder alignment enable high-performance outcomes in operational buildings. These recognitions highlight BREEAM's expanding U.S. footprint and its position as a trusted method for evaluating and improving building performance across all asset classes and lifecycle stages. BREEAM has been the world-leading sustainability assessment method for planning projects, infrastructure and buildings for over 30 years. There are now nearly 3 million BREEAM-registered buildings across 104 countries. In 2024, BREEAM saw robust expansion across North America, including a 43% increase in the total number of assets certified by BREEAM in the region. BRE's upcoming Version 7 update to BREEAM is set to drive progress across the commercial real estate sector by advancing sustainability efforts. With expanded carbon benchmarking, full lifecycle coverage, and streamlined data collection, the update will allow users greater access to the latest built environment innovations grounded in a rigorous, science-based approach. Learn more about the BREEAM Awards 2025 here. About BRE BRE is a world leading, multi-disciplinary, building science center with a mission to improve buildings and infrastructure, through cutting-edge research and knowledge generation. BRE maintains a range of products, services, standards and qualifications that are used around the world to bring about positive change in the built environment. Learn more at About BREEAM BRE developed BREEAM, the world's first and leading science-based family of standards defining and validating sustainability performance in the built environment. Since 1990, its third-party certified standards have helped improve asset performance at every stage, from design through construction, to use and refurbishment. Millions of buildings across the world are registered to work towards BREEAM's holistic approach to achieve ESG, health and Net Zero goals and 750,000+ certificates have been issued for assets in over 100 countries. Learn more about BREEAM in the US at
